Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.

The Neal Rosen Lab: Publications

Visit PubMed for a full listing of Neal Rosen’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. Gao Y, Chang MT, McKay D, Na N, Zhou B, Yaeger R, Torres NM, Muniz K, Drosten M, Barbacid M, Caponigro G, Stuart D, Moebitz H, Solit DB, Abdel-Wahab O, Taylor BS, Yao Z, Rosen N. Cancer Discov. 2018 May;8(5):648-66 doi: 10.1158/2159-8290.CD-17-1452. Epub 2018 Feb 26.

Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. Yaeger R, Yao Z, Hyman DM, Hechtman JF, Vakiani E, Zhao H, Su W, Wang L, Joelson A, Cercek A, Baselga J, de Stanchina E, Saltz L, Berger MF, Solit DB, Rosen N. Cancer Res. 2017 Dec 1;77(23):6513-6523. doi: 10.1158/0008-547CAN-17-0768. Epub 2017 Sep 26.

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, Drosten M, Zhao H, Cecchi F, Hembrough T, Michels J, Baumert H, Miles L, Campbell NM, de Stanchina E, Solit DB, Barbacid M, Taylor BS, Rosen N. Nature. 2017 Aug 10;548(7666):234-238. doi: 10.1038/nature23291. Epub 2017 Aug 2.

Rodrik-Outmezguine V, Okaniwa M, Yao Z, Novotny C, McWhirter C, Banaji A, Won H, Wong W, Berger M, de Stanchina E, Barratt D, Cosulich S, Klinowska T, Rosen N* and Shokat K*. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature, 2016; DOI: 10.1038/nature17963.*co-corresponding authors.

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Lito P, Solomon M, Li LS, Hansen R, Rosen N. Science. 2016 Feb 5;351(6273):604-8. doi: 10.1126/science.aad6204. Epub 2016 Jan 14.

BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Yao Z, Torres NM, Tao A, Gao Y, Luo L, Li Q, de Stanchina E, Abdel-Wahab O, Solit DB, Poulikakos PI, Rosen N. Cancer Cell. 2015 Sep 14;28(3):370-83. doi: 10.1016/j.ccell.2015.08.001. Epub 2015 Sep 3.

Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. Schwartz S, Wongvipat J, Trigwell CB, Hancox U, Carver BS, Rodrik-Outmezguine V, Will M, Yellen P, de Stanchina E, Baselga J, Scher HI, Barry ST, Sawyers CL, Chandarlapaty S, Rosen N. Cancer Cell. 2015 Jan 12;27(1):109-22. doi: 10.1016/j.ccell.2014.11.008. Epub 2014 Dec 24.

Tumor adaptation and resistance to RAF inhibitors. Lito P, Rosen N, Solit DB. Nat Med. 2013 Nov;19(11):1401-9. doi: 10.1038/nm.3392. Review.